The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma

This Phase 2, multi-center, single-arm study evaluates the safety, tolerability, and activity of neoadjuvant PRTX007 in combination with pembrolizumab in participants with resectable Stage III melanoma. Neoadjuvant immunotherapy has demonstrated improved clinical outcomes compared with adjuvant-only approaches, but there remains a need to enhance pathologic response rates without significant added toxicity. Participants will receive oral PRTX007, a Toll-like receptor 7 (TLR7) agonist prodrug, administered in combination with intravenous pembrolizumab prior to surgical resection. The primary o

Trial Details

NCT ID
NCT07565285
Phase
PHASE2
Sponsor
Primmune Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • PRTX007
  • Pembrolizumab
Locations (sample)
  • Waratah, New South Wales, Australia|-32.90667,151.72647
  • Cairns, Queensland, Australia|-16.92366,145.76613
  • Greenslopes, Queensland, Australia|-27.50815,153.04951
  • Woolloongabba, Queensland, Australia|-27.48855,153.03655
  • Melbourne, Victoria, Australia|-37.814,144.96332

Key Eligibility Criteria

  • Adults aged 18 years or older
  • Histologically confirmed, resectable Stage III cutaneous melanoma.
  • Candidate for curative-intent surgical resection
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →